Scholars Central

Research articlePublished 2 Feb 2016

Could Smokers’ Socio-Demographic and Housing Factors Affect and Influence the Choice Between Smoking Cessation Therapies?

Authors: Silvia Leone, Roberto Carrozzino, Monica Tassistro, Luigi Robbiano, Maria Laura Zuccoli, Francesca Romani, Antonietta Martelli, Francesca Mattioli

Clinical Pharmacology & Biopharmaceutics

Volume 5 · Issue 1 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: The published data suggest that interventions which combine pharmacotherapy and behavioural support increase success rates of smoking cessation compared to minimal intervention or usual care; however, a standardized behavioural psychotherapy programme has not been assessed yet. Our main aim was to assess if socio-demographic and housing characteristics of smokers attending an Italian smoking cessation centre, could have influenced the choice between varenicline therapy and psychological support only. Our secondary aims were: i) to evaluate the 6-month abstinence rates (ARs), confirmed by comparing exhaled air carbon monoxide concentrations, in smokers according to whether they took varenicline or received only psychological support; ii) to assess the most frequently reported adverse drug reactions (ADRs) by the varenicline group, mainly focusing on psychiatric events; iii) to evaluate the differences between men and women with regard to specific varenicline-related ADRs Method: 142 smokers were enrolled; all of them received the same psychological support programme. They were evaluated by a team of clinical experts, who advised them to opt for either one quitting method or the other; then the smokers chose themselves a treatment option of either varenicline plus psychotherapy (VAR: 78 patients) or psychotherapy alone (PSY: 64 patients). Results: Socio-demographic and psychological characteristics of patients have significantly influenced the treatment choice; the 6-month ARs were 35.9% versus 10.9% (p<0.01) in those using varenicline versus psychotherapy, respectively; 57.7% of the patients reported at least one adverse event. Conclusion: The analysis of socio-demographic factors and psychological characteristics of patients seems to be necessary to offer them the most effective therapy in order to achieve good abstinence rates. Therefore, this study confirms the data about the efficacy and safety of varenicline. Our screening methods and exclusion criteria seem to be valid aids to achieving good therapeutic outcomes with a low risk of occurrence of severe psychiatric events.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Pharmacology & Biopharmaceutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Silvia Leone”
  • BylineArticles whose byline prints “Roberto Carrozzino”
  • BylineArticles whose byline prints “Monica Tassistro”
  • BylineArticles whose byline prints “Luigi Robbiano”
  • BylineArticles whose byline prints “Maria Laura Zuccoli”
  • BylineArticles whose byline prints “Francesca Romani”
  • BylineArticles whose byline prints “Antonietta Martelli”
  • BylineArticles whose byline prints “Francesca Mattioli”